{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:10:21Z","timestamp":1788801021859,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oncological surgery is undergoing profound transformation driven by advances in systemic therapy, immunotherapy, and minimally invasive techniques. This narrative review examines whether open abdominal surgery retains clinical relevance in gynecological malignancies or has been superseded by modern alternatives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A literature search was conducted in PubMed combining terms related to gynecological malignancies, abdominal surgical procedures (open, laparoscopic, robotic, cytoreduction, pelvic exenteration), and personalized systemic therapies. Original articles, reviews, and guidelines in German and English were included. Two independent reviewers screened titles, abstracts, and full texts, extracting data on study design, interventions, and clinical endpoints (R0 resection, morbidity, progression-free and overall survival).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For cervical cancer, open radical abdominal hysterectomy as the standard of care was internationally confirmed. In endometrial cancer, minimally invasive approaches are established for early-stage disease, while laparotomy remains the gold standard in advanced stages requiring cytoreductive surgery. For ovarian, tubal, and primary peritoneal carcinoma, open cytoreductive surgery with the goal of macroscopically complete resection remains guideline recommended. Emerging biomarkers such as circulating tumor DNA may further refine patient selection and surgical decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Open abdominal surgery remains indispensable in gynecological oncology. Rather than being replaced, it is evolving into a specialized, biology-adapted component of multimodal treatment strategies. Surgical indications are becoming less frequent but more complex and individualized. Patient selection in experienced centers remains the decisive factor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-026-04510-4","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:44:28Z","timestamp":1788756268000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The evolving role of open abdominal surgery in gynecological malignancies in the era of minimally invasive and precision oncology"],"prefix":"10.1186","volume":"24","author":[{"given":"Miklos","family":"Acs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Tempfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Lampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"4510_CR1","doi-asserted-by":"publisher","first-page":"e4851","DOI":"10.1016\/j.ajog.2009.06.015","volume":"201 5","author":"N Bansal","year":"2009","unstructured":"Bansal N, Herzog TJ, Shaw RE, Burke WM, Deutsch I, Wright JD. Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation. Am J Obstet Gynecol. 2009;201 5:e4851\u20139.","journal-title":"Am J Obstet Gynecol"},{"key":"4510_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ijgo.70277","volume":"171","author":"N Bhatla","year":"2025","unstructured":"Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2025 update. Int J Gynecol Obstet. 2025;171:87\u2013108. https:\/\/doi.org\/10.1002\/ijgo.70277.","journal-title":"Int J Gynecol Obstet"},{"key":"4510_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(97)02250-2","volume":"350","author":"F Landoni","year":"1997","unstructured":"Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350:535\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(97)02250-2.","journal-title":"Lancet"},{"key":"4510_CR4","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1056\/NEJMoa1806395","volume":"379","author":"PT Ramirez","year":"2018","unstructured":"Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med. 2018;379:1895\u2013904. https:\/\/doi.org\/10.1056\/NEJMoa1806395.","journal-title":"N Engl J Med"},{"key":"4510_CR5","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404:1321\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(24)01808-7.","journal-title":"Lancet"},{"key":"4510_CR6","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom. 2022. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/zervixkarzinom. Accessed 4 Jan 2026."},{"key":"4510_CR7","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1200\/JCO.23.02335","volume":"42","author":"PT Ramirez","year":"2024","unstructured":"Ramirez PT, Robledo KP, Frumovitz M, Pareja R, Ribeiro R, Lopez A, et al. LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. J Clin Oncol. 2024;42:2741\u20136. https:\/\/doi.org\/10.1200\/JCO.23.02335.","journal-title":"J Clin Oncol"},{"key":"4510_CR8","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1804923","volume":"379","author":"A Melamed","year":"2018","unstructured":"Melamed A, Margul DJ, Chen L, Keating NL, del Carmen MG, Yang J, et al. Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. N Engl J Med. 2018;379:1905\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1804923.","journal-title":"N Engl J Med"},{"key":"4510_CR9","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1001\/jamaoncol.2020.1694","volume":"6","author":"R Nitecki","year":"2020","unstructured":"Nitecki R, Ramirez PT, Frumovitz M, Krause KJ, Tergas AI, Wright JD, et al. Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2020;6:1019\u201327. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1694.","journal-title":"JAMA Oncol"},{"key":"4510_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","volume":"21","author":"N Abu-Rustum","year":"2023","unstructured":"Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, et al. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21:181\u2013209. https:\/\/doi.org\/10.6004\/jnccn.2023.0006.","journal-title":"J Natl Compr Canc Netw"},{"key":"4510_CR11","unstructured":"Commissioner O of the. Cervical Cancer 101: What Every Woman Needs to Know. FDA. 2025."},{"key":"4510_CR12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12885-022-09494-4","volume":"22","author":"X Wu","year":"2022","unstructured":"Wu X, Feng H, Gao S, Feng H, Diao W, Zhang H, et al. A multicenter noninferior randomized controlled study comparing the efficacy of laparoscopic versus abdominal radical hysterectomy for cervical cancer (stage IA1 with LVSI, IA2): study protocol of the LAUNCH 1 trial. BMC Cancer. 2022;22:384. https:\/\/doi.org\/10.1186\/s12885-022-09494-4.","journal-title":"BMC Cancer"},{"key":"4510_CR13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/s13063-023-07573-w","volume":"24","author":"X Wu","year":"2023","unstructured":"Wu X, Yu H, Bai Y, Hou Y, Lou W, Wang X, et al. A multicenter noninferior randomized controlled study comparing the efficacy of laparoscopic versus abdominal radical hysterectomy for cervical cancer (stage IB3 and IIA2): study protocol of the LAUNCH 3 trial. Trials. 2023;24:542. https:\/\/doi.org\/10.1186\/s13063-023-07573-w.","journal-title":"Trials"},{"key":"4510_CR14","doi-asserted-by":"publisher","unstructured":"Leitao MM Jr, Bixel KL, Chase DM, Quick A, McCormick C, Black D, et al. ROCC\/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer. Int J Gynecol Cancer. 2025;35. https:\/\/doi.org\/10.1016\/j.ijgc.2025.101760.","DOI":"10.1016\/j.ijgc.2025.101760"},{"key":"4510_CR15","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1136\/ijgc-2019-000558","volume":"29","author":"H Falconer","year":"2019","unstructured":"Falconer H, Palsdottir K, Stalberg K, Dahm-K\u00e4hler P, Ottander U, Lundin ES, et al. Robot-assisted approach to cervical cancer (RACC): an international multi-center, open-label randomized controlled trial. Int J Gynecol Cancer. 2019;29:1072\u20136. https:\/\/doi.org\/10.1136\/ijgc-2019-000558.","journal-title":"Int J Gynecol Cancer"},{"key":"4510_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2020.10.037","volume":"143","author":"D Cibula","year":"2021","unstructured":"Cibula D, Dostalek L, Hillemanns P, Scambia G, Jarkovsky J, Persson J, et al. Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study. Eur J Cancer. 2021;143:88\u2013100. https:\/\/doi.org\/10.1016\/j.ejca.2020.10.037.","journal-title":"Eur J Cancer"},{"key":"4510_CR17","doi-asserted-by":"publisher","unstructured":"Hinojosa-Gonzalez DE, Escarcega-Bordagaray JA, Murillo-Torres RM, Torres-Martinez M, Heredia FM. Immune checkpoint therapy in locally advanced, persistent, recurrent, and metastatic cervical cancer: A systematic review and Bayesian network meta-analysis. Int J Gynecol Obstet n\/a n\/a. https:\/\/doi.org\/10.1002\/ijgo.70648","DOI":"10.1002\/ijgo.70648"},{"key":"4510_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ygyno.2011.03.003","volume":"122","author":"T Benn","year":"2011","unstructured":"Benn T, Brooks RA, Zhang Q, Powell MA, Thaker PH, Mutch DG, et al. Pelvic exenteration in gynecologic oncology: A single institution study over 20 years. Gynecol Oncol. 2011;122:14\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2011.03.003.","journal-title":"Gynecol Oncol"},{"key":"4510_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1136\/ijgc-00009577-200307000-00014","volume":"13","author":"Y ERALP","year":"2003","unstructured":"ERALP Y, SAIP P, SAKAR B, KUCUCUK S, AYDINER A, DINCER M, et al. Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer. 2003;13:497\u2013504. https:\/\/doi.org\/10.1136\/ijgc-00009577-200307000-00014.","journal-title":"Int J Gynecol Cancer"},{"key":"4510_CR20","doi-asserted-by":"publisher","unstructured":"Lampe B, Luengas-W\u00fcrzinger V, Weitz J, Roth S, Rawert F, Schuler E, et al. Opportunities and Limitations of Pelvic Exenteration Surgery. Cancers. 2021;13. https:\/\/doi.org\/10.3390\/cancers13246162.","DOI":"10.3390\/cancers13246162"},{"key":"4510_CR21","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Leitlinienprogramm Onkologie: Endometriumkarzinom. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/endometriumkarzinom. Accessed 8 Jan 2026."},{"key":"4510_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/ijgo.14923","volume":"162","author":"JS Berek","year":"2023","unstructured":"Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, et al. FIGO staging of endometrial cancer: 2023. Int J Gynecol Obstet. 2023;162:383\u201394. https:\/\/doi.org\/10.1002\/ijgo.14923.","journal-title":"Int J Gynecol Obstet"},{"key":"4510_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006655.pub2","author":"K Galaal","year":"2012","unstructured":"Galaal K, Bryant A, Fisher AD, Al-Khaduri M, Kew F, Lopes A. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Reviews. 2012. https:\/\/doi.org\/10.1002\/14651858.CD006655.pub2.","journal-title":"Cochrane Database Syst Reviews"},{"key":"4510_CR24","doi-asserted-by":"publisher","first-page":"5331","DOI":"10.1200\/JCO.2009.22.3248","volume":"27","author":"JL Walker","year":"2009","unstructured":"Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Laparoscopy Compared With Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009;27:5331\u20136. https:\/\/doi.org\/10.1200\/JCO.2009.22.3248.","journal-title":"J Clin Oncol"},{"key":"4510_CR25","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1001\/jama.2017.2068","volume":"317","author":"M Janda","year":"2017","unstructured":"Janda M, Gebski V, Davies LC, Forder P, Brand A, Hogg R, et al. Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer: A Randomized Clinical Trial. JAMA. 2017;317:1224\u201333. https:\/\/doi.org\/10.1001\/jama.2017.2068.","journal-title":"JAMA"},{"key":"4510_CR26","doi-asserted-by":"publisher","first-page":"e1851","DOI":"10.1002\/rcs.1851","volume":"13","author":"T Ind","year":"2017","unstructured":"Ind T, Laios A, Hacking M, Nobbenhuis M. A comparison of operative outcomes between standard and robotic laparoscopic surgery for endometrial cancer: A systematic review and meta-analysis. Int J Med Rob Comput Assist Surg. 2017;13:e1851. https:\/\/doi.org\/10.1002\/rcs.1851.","journal-title":"Int J Med Rob Comput Assist Surg"},{"key":"4510_CR27","unstructured":"FDA Oncology Center of Excellence Presents: Conversations on Cancer. Endometrial Cancer: Rising incidence. Rising innovation. \u2013\u200909\/18\/2025. FDA. 2025. https:\/\/www.fda.gov\/news-events\/fda-meetings-conferences-and-workshops\/fda-oncology-center-excellence-presents-conversations-cancer-endometrial-cancer-rising-incidence. Accessed 27 Dec 2025."},{"key":"4510_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ygyno.2017.05.027","volume":"146","author":"RW Holloway","year":"2017","unstructured":"Holloway RW, Abu-Rustum NR, Backes FJ, Boggess JF, Gotlieb WH, Jeffrey Lowery W, et al. Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol. 2017;146:405\u201315. https:\/\/doi.org\/10.1016\/j.ygyno.2017.05.027.","journal-title":"Gynecol Oncol"},{"key":"4510_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ygyno.2010.04.005","volume":"118","author":"JN Barlin","year":"2010","unstructured":"Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: A meta-analysis. Gynecol Oncol. 2010;118:14\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2010.04.005.","journal-title":"Gynecol Oncol"},{"key":"4510_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"DA Levine","year":"2013","unstructured":"Levine DA, Getz G, Gabriel SB, Cibulskis K, Lander E, Sivachenko A, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67\u201373. https:\/\/doi.org\/10.1038\/nature12113.","journal-title":"Nature"},{"key":"4510_CR31","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1200\/JCO.20.00549","volume":"38","author":"A Le\u00f3n-Castillo","year":"2020","unstructured":"Le\u00f3n-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol. 2020;38:3388\u201397. https:\/\/doi.org\/10.1200\/JCO.20.00549.","journal-title":"J Clin Oncol"},{"key":"4510_CR32","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","volume":"388","author":"MR Mirza","year":"2023","unstructured":"Mirza MR, Chase DM, Slomovitz BM, Christensen R, dePont, Nov\u00e1k Z, Black D, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023;388:2145\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2216334.","journal-title":"N Engl J Med"},{"key":"4510_CR33","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","volume":"388","author":"RN Eskander","year":"2023","unstructured":"Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023;388:2159\u201370. https:\/\/doi.org\/10.1056\/NEJMoa2302312.","journal-title":"N Engl J Med"},{"key":"4510_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ygyno.2016.07.090","volume":"143","author":"A Talhouk","year":"2016","unstructured":"Talhouk A, Hoang LN, McConechy MK, Nakonechny Q, Leo J, Cheng A, et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. Gynecol Oncol. 2016;143:46\u201353. https:\/\/doi.org\/10.1016\/j.ygyno.2016.07.090.","journal-title":"Gynecol Oncol"},{"key":"4510_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bpobgyn.2017.05.005","volume":"45","author":"A Lucidi","year":"2017","unstructured":"Lucidi A, Chiantera V, Gallotta V, Ercoli A, Scambia G, Fagotti A. Role of robotic surgery in ovarian malignancy. Best Pract Res Clin Obstet Gynecol. 2017;45:74\u201382. https:\/\/doi.org\/10.1016\/j.bpobgyn.2017.05.005.","journal-title":"Best Pract Res Clin Obstet Gynecol"},{"key":"4510_CR36","doi-asserted-by":"publisher","unstructured":"Park HJ, Kim DW, Yim GW, Nam EJ, Kim S, Kim YT. Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis. Am J Obstet Gynecol. 2013;209:58.e1-58.e8. https:\/\/doi.org\/10.1016\/j.ajog.2013.04.013.\u00a0","DOI":"10.1016\/j.ajog.2013.04.013"},{"key":"4510_CR37","doi-asserted-by":"publisher","unstructured":"Facer B, Wang F, Grijalva CG, Alvarez RD, Shu X-O. Survival outcomes for robotic-assisted laparoscopy versus traditional laparoscopy in clinical stage I epithelial ovarian cancer. Am J Obstet Gynecol. 2020;222:474.e1-474.e12. https:\/\/doi.org\/10.1016\/j.ajog.2019.10.104.\u00a0","DOI":"10.1016\/j.ajog.2019.10.104"},{"key":"4510_CR38","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ejso.2012.12.003","volume":"39","author":"HS Kim","year":"2013","unstructured":"Kim HS, Ahn JH, Chung HH, Kim JW, Park NH, Song YS, et al. Impact of intraoperative rupture of the ovarian capsule on prognosis in patients with early-stage epithelial ovarian cancer: A meta-analysis. Eur J Surg Oncol. 2013;39:279\u201389. https:\/\/doi.org\/10.1016\/j.ejso.2012.12.003.","journal-title":"Eur J Surg Oncol"},{"key":"4510_CR39","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamaoncol.2020.1702","volume":"6","author":"K Matsuo","year":"2020","unstructured":"Matsuo K, Huang Y, Matsuzaki S, Klar M, Roman LD, Sood AK, et al. Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer. JAMA Oncol. 2020;6:1110\u20133. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1702.","journal-title":"JAMA Oncol"},{"key":"4510_CR40","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","volume":"19","author":"I Vergote","year":"2018","unstructured":"Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018;19:1680\u20137. https:\/\/doi.org\/10.1016\/S1470-2045(18)30566-7.","journal-title":"Lancet Oncol"},{"key":"4510_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ygyno.2023.01.017","volume":"172","author":"K Jorgensen","year":"2023","unstructured":"Jorgensen K, Melamed A, Wu C-F, Nitecki R, Pareja R, Fagotti A, et al. Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy. Gynecol Oncol. 2023;172:130\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2023.01.017.","journal-title":"Gynecol Oncol"},{"key":"4510_CR42","unstructured":"Commissioner O. of the. FDA In Brief: FDA cautions patients, providers about using robotically-assisted surgical devices for mastectomy and other cancer-related surgeries. FDA. 2019."},{"key":"4510_CR43","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Leitlinienprogramm Onkologie: Ovarialkarzinom. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/ovarialkarzinom\/?utm_source=copilot.com. Accessed 9 Jan 2026."},{"key":"4510_CR44","doi-asserted-by":"publisher","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","volume":"22","author":"J Liu","year":"2024","unstructured":"Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA, et al. NCCN Guidelines\u00ae Insights: Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer, Version 3.2024: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2024;22:512\u20139. https:\/\/doi.org\/10.6004\/jnccn.2024.0052.","journal-title":"J Natl Compr Canc Netw"},{"key":"4510_CR45","doi-asserted-by":"publisher","first-page":"e2446325","DOI":"10.1001\/jamanetworkopen.2024.46325","volume":"7","author":"JA Rauh-Hain","year":"2024","unstructured":"Rauh-Hain JA, Melamed A, Pareja R, May T, Sinno A, McNally L, et al. Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy in High-Grade Epithelial Ovarian Cancer: A LANCE Randomized Clinical Trial. JAMA Netw Open. 2024;7:e2446325\u20132446325. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.46325.","journal-title":"JAMA Netw Open"},{"key":"4510_CR46","doi-asserted-by":"publisher","unstructured":"Ceccaroni M, Roviglione G, Bruni F, Dababou S, Venier M, Zorzi C, et al. Things Have Changed\u2014Laparoscopic Cytoreduction for Advanced and Recurrent Ovarian Cancer: The Experience of a Referral Center on 108 Patients. Cancers. 2023;15. https:\/\/doi.org\/10.3390\/cancers15245726.","DOI":"10.3390\/cancers15245726"},{"key":"4510_CR47","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/ijgc-2022-003904","volume":"33","author":"C Conte","year":"2023","unstructured":"Conte C, Marchetti C, Loverro M, Te Giudice M, resa, Rosati A, Gallotta V, et al. Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer. Int J Gynecol Cancer. 2023;33:137\u201344. https:\/\/doi.org\/10.1136\/ijgc-2022-003904.","journal-title":"Int J Gynecol Cancer"},{"key":"4510_CR48","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1136\/ijgc-2024-005265","volume":"34","author":"C Uwins","year":"2024","unstructured":"Uwins C, Assalaarachchi H, Bennett K, Read J, Tailor A, Crawshaw J, et al. MIRRORS: a prospective cohort study assessing the feasibility of robotic interval debulking surgery for advanced-stage ovarian cancer. Int J Gynecol Cancer. 2024;34:886\u201397. https:\/\/doi.org\/10.1136\/ijgc-2024-005265.","journal-title":"Int J Gynecol Cancer"},{"key":"4510_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejogrb.2022.11.005","volume":"280","author":"P Van Trappen","year":"2023","unstructured":"Van Trappen P, de Cuypere E, Claes N. Robotic surgery in early and advanced ovarian cancer: Case selection for surgical staging and interval debulking surgery. Eur J Obstet Gynecol Reproductive Biology. 2023;280:7\u201311. https:\/\/doi.org\/10.1016\/j.ejogrb.2022.11.005.","journal-title":"Eur J Obstet Gynecol Reproductive Biology"},{"key":"4510_CR50","doi-asserted-by":"publisher","unstructured":"Hayek J, An A, Wolf J, Lamiman K, Kim M, Knochenhauer H, et al. Overall Survival Following Interval Complete Gross Resection of Advanced Ovarian Cancer via Laparoscopy Versus Open Surgery: An Analysis of the National Cancer Database. J Clin Med. 2025;14. https:\/\/doi.org\/10.3390\/jcm14041164.","DOI":"10.3390\/jcm14041164"},{"key":"4510_CR51","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1808424","volume":"380","author":"P Harter","year":"2019","unstructured":"Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. N Engl J Med. 2019;380:822\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1808424.","journal-title":"N Engl J Med"},{"key":"4510_CR52","doi-asserted-by":"publisher","first-page":"101463","DOI":"10.1016\/j.gore.2024.101463","volume":"54","author":"P Bhati","year":"2024","unstructured":"Bhati P, Thomas A, George Chandy R, Datta A, Susan Thomas D, Thomas V, et al. Secondary cytoreduction in recurrent ovarian cancer- experience from a tertiary care centre in India. Gynecologic Oncol Rep. 2024;54:101463. https:\/\/doi.org\/10.1016\/j.gore.2024.101463.","journal-title":"Gynecologic Oncol Rep"},{"key":"4510_CR53","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","volume":"30","author":"A Fagotti","year":"2020","unstructured":"Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020;30:1657\u201364. https:\/\/doi.org\/10.1136\/ijgc-2020-001640.","journal-title":"Int J Gynecol Cancer"},{"key":"4510_CR54","doi-asserted-by":"publisher","unstructured":"Kallio HM, Savolainen K, Virtanen T, Ryypp\u00f6 L, Selin H, Martikainen P, et al. Sensitive circulating tumor DNA\u2013based residual disease detection in epithelial ovarian cancer. Life Sci Alliance. 2024;7. https:\/\/doi.org\/10.26508\/lsa.202402658.","DOI":"10.26508\/lsa.202402658"},{"key":"4510_CR55","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1245\/s10434-021-11316-z","volume":"29","author":"J-F Zhang","year":"2022","unstructured":"Zhang J-F, Lv L, Zhao S, Zhou Q, Jiang C-G. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: A 12-Year Meta-Analysis of this Promising Treatment Strategy for Advanced Gastric Cancer at Different Stages. Ann Surg Oncol. 2022;29:3170\u201386. https:\/\/doi.org\/10.1245\/s10434-021-11316-z.","journal-title":"Ann Surg Oncol"},{"key":"4510_CR56","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, van Leeuwen JHS, Schreuder HWR, Hermans RHM, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018;378:230\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1708618.","journal-title":"N Engl J Med"},{"key":"4510_CR57","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S1470-2045(24)00531-X","volume":"25","author":"J-M Classe","year":"2024","unstructured":"Classe J-M, Meeus P, Hudry D, Wernert R, Quenet F, Marchal F, et al. Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2024;25:1551\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(24)00531-X.","journal-title":"Lancet Oncol"},{"key":"4510_CR58","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1200\/JCO.24.00686","volume":"43","author":"A Fagotti","year":"2025","unstructured":"Fagotti A, Costantini B, Fanfani F, Giannarelli D, De Iaco P, Chiantera V, et al. Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18). J Clin Oncol. 2025;43:852\u201360. https:\/\/doi.org\/10.1200\/JCO.24.00686.","journal-title":"J Clin Oncol"},{"key":"4510_CR59","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/ijgc-2019-000682","volume":"29","author":"A Reuss","year":"2019","unstructured":"Reuss A, du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G, et al. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33\/AGO-OVAR OP7). Int J Gynecol Cancer. 2019;29:1327\u201331. https:\/\/doi.org\/10.1136\/ijgc-2019-000682.","journal-title":"Int J Gynecol Cancer"},{"key":"4510_CR60","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386:249\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(14)62223-6.","journal-title":"Lancet"},{"key":"4510_CR61","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa2308900","volume":"390","author":"M Plante","year":"2024","unstructured":"Plante M, Kwon JS, Ferguson S, Samou\u00eblian V, Ferron G, Maulard A, et al. Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer. N Engl J Med. 2024;390:819\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2308900.","journal-title":"N Engl J Med"},{"key":"4510_CR62","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(24)01438-7","volume":"404","author":"M McCormack","year":"2024","unstructured":"McCormack M, Eminowicz G, Gallardo D, Diez P, Farrelly L, Kent C, et al. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial. Lancet. 2024;404:1525\u201335. https:\/\/doi.org\/10.1016\/S0140-6736(24)01438-7.","journal-title":"Lancet"},{"key":"4510_CR63","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.23.02132","volume":"42","author":"SN Westin","year":"2024","unstructured":"Westin SN, Moore K, Chon HS, Lee J-Y, Thomes Pepin J, Sundborg M, et al. Durvalumab Plus Carboplatin\/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol. 2024;42:283\u201399. https:\/\/doi.org\/10.1200\/JCO.23.02132.","journal-title":"J Clin Oncol"},{"key":"4510_CR64","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","volume":"25","author":"N Colombo","year":"2024","unstructured":"Colombo N, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, et al. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024;25:1135\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(24)00334-6.","journal-title":"Lancet Oncol"},{"key":"4510_CR65","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s11701-024-01867-0","volume":"18","author":"JE Knudsen","year":"2024","unstructured":"Knudsen JE, Ghaffar U, Ma R, Hung AJ. Clinical applications of artificial intelligence in robotic surgery. J Robotic Surg. 2024;18:102. https:\/\/doi.org\/10.1007\/s11701-024-01867-0.","journal-title":"J Robotic Surg"},{"key":"4510_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2024.1393898","author":"MX Morris","year":"2024","unstructured":"Morris MX, Fiocco D, Caneva T, Yiapanis P, Orgill DP. Current and future applications of artificial intelligence in surgery: implications for clinical practice and research. Front Surg. 2024. https:\/\/doi.org\/10.3389\/fsurg.2024.1393898. 11-2024.","journal-title":"Front Surg"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04510-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04510-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04510-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:03:36Z","timestamp":1788800616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04510-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4510"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04510-4","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"9 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. For this article no animal or human data or tissue has been utilized.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain data from any individual person.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"360"}}